Skip to main content

Jordi Barquinero Mañez

I am an MD, specialized in Internal Medicine, and senior researcher at the Vall d'Hebron Research Institute (VHIR). Doctor from the UAB with Extraordinary Award. I received post-doctoral training at the Fred Hutchinson Cancer Research Center (Seattle). I am currently leading the Gene and Cell Therapy group at the VHIR. My interest has focused on understanding disease mechanisms and finding effective therapies for orphan diseases. In our laboratory we have worked on gene therapy research projects for several rare diseases, mainly of genetic origin.

Institutions of which they are part

Head of group
Gene and Cell Therapy
Vall Hebron Institut de Recerca

Jordi Barquinero Mañez

Institutions of which they are part

Head of group
Gene and Cell Therapy
Vall Hebron Institut de Recerca

I am an MD, specialized in Internal Medicine, and senior researcher at the Vall d'Hebron Research Institute (VHIR). Doctor from the UAB with Extraordinary Award. I received post-doctoral training at the Fred Hutchinson Cancer Research Center (Seattle). I am currently leading the Gene and Cell Therapy group at the VHIR. My interest has focused on understanding disease mechanisms and finding effective therapies for orphan diseases. In our laboratory we have worked on gene therapy research projects for several rare diseases, mainly of genetic origin.

I am an MD specialized in Internal Medicine (Vall d'Hebron University Hospital). I worked at the Intensive Care Unit (HUVH) and the Emergency Department of the Hospital de l'Esperança. I did pre-doctoral studies on autoimmunity at the University of Louisville (Dr. N. Harris) and got my PhD at the Autonomous University of Barcelona with Extraordinary Award, with a work that contributed to the description of a new disease, the primary antiphospholipid syndrome. I was a postdoc at the Fred Hutchinson Cancer Research Center (Dr. R. Storb, Seattle), where I was trained in hematopoietic stem cell gene therapy. I am currently group leader of the gene and cell therapy group (VHIR), where we investigate new therapeutic strategies for rare genetic diseases, mostly in collaboration with other groups on campus and from other national and international institutions. We have participated in research projects using models of multiple sclerosis, hemophilia, MNGIE, in a clinical trial for Fanconi anemia type A (coordinated by Drs. J. Bueren and P. Río, at the CIEMAT (Madrid)), and more recently, in a novel gene therapy approach for muscular dystrophy due to merosin deficiency, in collaboration with the Pediatric Neurology group (Drs. F. Munell and D. Gómez). Our group is part of the national network TERAV (RICORS). I have participated in European projects (INHERINET, CONSERT), including one as coordinator (HEMO-IPS, e-Rare-2), in which we experimentally demonstrated the mutagenic mechanism of the "Royal disease", the form of hemophilia B that affected several European royal families in the 19th and 20th centuries. I participate as a teacher in different master's degrees and I am a member of the American and European Gene and Cell Therapy Societies, and was one of the founding members of the Spanish Society of Gene and Cell Therapy.

Projects

Terapia génica para el tratamiento del MNGIE (Mitochondrial Neurogastrointestinal Encephalomyopathy). Introducción del gen timidina fosforilasa en líneas celulares humanas y en un doble knock-out murino como modelos experimentales

IP: Ramon Martí Seves
Collaborators: Jordi Barquinero Mañez, Marc Pellicer Sarasa
Funding agency: Instituto de Salud Carlos III
Funding: 180895
Reference: PI060735
Duration: 01/01/2007 - 30/12/2009

Inducció de tolerància mitjançant el quimerisme molecular: la encefalomielitis autoimmune experimental com a model. Mecanismes cel·lulars i optimització

IP: Jordi Barquinero Mañez
Collaborators: -
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 955
Reference: 2006FI 00664
Duration: 01/01/2006 - 31/12/2009

Quimerismo molecular como inductor de tolerancia en la encefalomielitis autoinmune experimental: mecanismos y optimización

IP: Jordi Barquinero Mañez
Collaborators: Francisco Vidal Pérez, Herena Eixarch Ahufinger, Carmen Espejo Ruiz
Funding agency: Instituto de Salud Carlos III
Funding: 177310
Reference: PI051441
Duration: 01/01/2006 - 31/12/2009

Concerted safety & efficiency evaluation of retroviral transgenesis in gene therapy of inherited diseases. Acronym: CONCERT FP6, Integrated Project Contract No 005242 LSHB-CT-2004-005242

IP: Jordi Barquinero Mañez
Collaborators: Herena Eixarch Ahufinger
Funding agency: EUROPEAN COMMISSION
Funding: 307500
Reference: FP6-CONSERT-5242
Duration: 01/01/2005 - 01/01/2009

Related news

Over the course of two days, experts presented the latest advances in vectors, different gene modification techniques and their transfer to clinical practice.

Related professionals

David Gurwitz

David Gurwitz

Senior researcher
Systemic Diseases
Read more
SILVIA GARTNER TIZZANO

SILVIA GARTNER TIZZANO

Main researcher
Growth and Development
Read more
Luca Basile

Luca Basile

Administration and Management
Microbiology
Read more
Ana  Leon  Espitia

Ana Leon Espitia

Predoctoral researcher
Research Group of Physical Medicine and Rehabilitation
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.